Rhinomed Ltd (ASX:RNO) (OTCMKTS:RHNMF) are pleased to provide the Company's latest Investor Update for May 2017.
Rhinomed Limited (ASX:RNO) is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the sport, sleep, cough/cold and allergy, and drug delivery markets. The company has two products in market (the Turbine for sports and exercise and Mute for snoring and better sleep) and has recently completed a pilot Phase I clinical trial of its new INPEAP technology targeting mild to moderate sleep apnea. For more information, go to www.rhinomed.global.
Respiratory technology company Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) is pleased to announce that it has been advised by Sigma Healthcare (ASX:SIG) that Mute sleep technology will form part of the 2017 core range for the Amcal and Guardian pharmacy brands.
Respiratory technology company Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) is pleased to announce further expansion of its North American retail distribution footprint having received confirmation that its Mute sleep technology will go on sale in 811 GNC Holdings Inc. health, wellness and performance stores.
Rhinomed (ASX:RNO) advises it has undertaken a AUD$2.19 million private placement to two US based sophisticated investor groups as part of its 15% placement capacity. In addition, the company has flagged its intention to hold a General Meeting to approve a capital management initiative that will seek to consolidate the company's capital and provide a sale of less than marketable share parcels facility.
Rhinomed (ASX:RNO) is pleased to provide an update on the expansion of its global distribution program. The company can report that Rhinomed has been added as a vendor by two major US based pharmacy wholesalers and the successful expansion of the listing of its Mute Sleep technology by Symbion in Australia.
Rhinomed (ASX:RNO) has had a strong first quarter of the financial year with positive traction across its consumer health and clinical businesses.
Rhinomed Ltd (ASX:RNO) has launched two products into global markets during the financial year: launching our new sleep quality aid, Mute(TM) into the global sleep device market and a new generation Turbine(TM) sports product in response to feedback from users.
Rhinomed Limited (ASX:RNO) is pleased to announce today that it has raised a total of A$2.5m by a way of a placement of 78,125,000 fully paid ordinary shares at A$0.032 per shares with institutional, Sophisticated, and Offshore investors (placement).
Australian respiratory technology company, Rhinomed (ASX:RNO) is pleased to announce it has entered into a landmark partnership with SleepGP, a growing network of GP practices, to raise awareness of sleep disordered breathing issues within the family medicine setting.
Rhinomed Ltd (ASX:RNO) has been building its international presence and connections amongst the international investment and pharmaceutical community this year. In March, Michael Johnson was the keynote 'Rising Star' presentation at the Master Investor Show in London.